

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

	Attorney Docket No.	C1037/7025/HCL/MAT		
	First Named	P TO		
	Robert L. Bratzler	7999		
	Express Mail Label No	EL844533552US	56 U	2/18
	Date of Deposit	December 14, 2001	JCB	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ADDRESS Box Patent Application TO: Commissioner for Patents Washington, DC 20231	
Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	8. CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)	
2. Applicant claims small entity status. See 37 CFR 1.27.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
3. Specification -Total pages 69 60 - pages description 1 - pages abstract 8 - pages claims 74- Total claims	 a. ☑ Computer Readable Form (CRF) b. ☑ Specification Sequence Listing on: i.□ CD-ROM or CD-R (2 copies); or ii. ☑ paper (identical to computer copy) c. ☑ Statement verifying identity of above copies 	
4. ☑ Drawing(s) (35 USC 113) 1 - Total sheets	ACCOMPANYING APPLICATION PARTS	
☑Informal ☐ Formal 1 - Total drawings	10. ☐ Assignment Papers/cover sheet &	
5. Oath or Declaration - Total pages	documents(s)	
a. Newly executed (original or copy)	11. □ 37 CFR 3.73(b) Statement (when there is an assignee)	
b. D Copy from a prior application (37 CFR 1 63(d)) (for continuation/divisional with Box 18 completed)	☐ Power of Attorney	
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	12. ☐ English Translation of Document (if applicable)	
	13. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations	
,,,,	14. □ Preliminary Amendment	
☐ Incorporation by Reference (usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is	15. ☑ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by	16. 口 Certified Copy of Priority Document(s) (if foreign priority is claimed)	
reference therein. See 19.	17. Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)	
7. 团 Application Data Sheet, See 37 CFR 1.76	18. ☑ Other: This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Patent Application Serial No. 60/255,534 filed on December 14, 2000, entitled INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS The entire contents of the provisional application are hereby expressly incorporated by reference.	

و کا دار کی کرد برای کی کرد برای کا در این استان استان کرد برای کرد برای برای برای برای کرد برای استان کرد برای استان کرد برای کرد برای برای کرد برای									
19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:									
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:, filed on, entitled and now									
☐ Cancel in this application claims before calculating the filing fee.									
☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:									
This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:, filed on, entitled and now									
Prior application information: Examiner Group Art Unit:									
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.									
	20. CORRESP	ONDENCE AD	DRESS						
Correspondence address	below								
CUSTOMER NUMBER: 23628									
OR									
AGENT'S NAME	AGENT'S NAME Maria A. Trevisan								
FIRM NAME	FIRM NAME Wolf, Greenfield & Sacks, P.C.								
ADDRESS	ADDRESS 600 Atlantic Avenue								
CITY	Boston	STATE	MA	ZIP	02210				
COUNTRY USA		TELEPHONE	(617) 720-3500	FAX	(617) 720-2441				
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED									
NAME Maria A. Trevisan, Reg. No. 48,207									
SIGNATURE									
De COMBER 14, 2001									

ATTORNEY DOCKET NUMBER: C1037/7025/HCL/MAT Express Mail Label No.: EL844533552US Date of Deposit: December 14, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Robert L. Bratzler

Serial No.

Not Yet Assigned

Filed:


December 14, 2001 (Herewith)

For: Examiner:

INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS

Art Unit:

Not Yet Assigned Not Yet Assigned



Sir:

STATEMENT PURSUANT TO 37 C.F.R. §1.821(f)

This statement is made pursuant to 37 C.F.R. §1.821(f). Applicant's enclose herewith an original written copy of the Sequence Listing and a computer readable diskette. Applicant's representative states that the information recorded in the computer readable form is identical to the written Sequence Listing.

Respectfully submitted,

Maria A. Trevisan, Reg. No. 48,207 WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue Boston, MA 02210-2211

(617)720-3500

Attorney's Doc. No.: C1037/7025(HCL/MAT)

December 14, 2001

X12/14/01